

# Oklahoma Health Care Authority

## Drug Utilization Review Board (DUR Board)

Meeting – June 9, 2021 @ 4:00pm

at the

Oklahoma Health Care Authority (OHCA)

4345 N. Lincoln Blvd.

Oklahoma City, Oklahoma 73105

**NOTE:** *For all DUR Board members, College of Pharmacy presenters, and any speakers who sign up in advance for public comment, this meeting will be held in person at OHCA (see address above). In response to COVID-19, temperature checks will be required for all in person attendees. For additional information on OHCA's COVID-19 precautions and protocols for admittance into the Agency, please go to [www.oklahoma.gov/ohca](http://www.oklahoma.gov/ohca).*

*There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.*

### **Viewing Access Only:**

Please register for the meeting at:

[https://zoom.us/webinar/register/WN\\_dgGOMPbDRuuDIZWND8TjHQ](https://zoom.us/webinar/register/WN_dgGOMPbDRuuDIZWND8TjHQ)

After registering, you will receive a confirmation email containing information about joining the webinar.

### **AGENDA**

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

#### **1. Call to Order**

A. Roll Call – Dr. Wilcox

#### **DUR Board Members:**

Dr. Stephen Anderson –	participating in person
Dr. Jennifer de los Angeles –	participating in person
Ms. Jennifer Boyett –	participating in person
Dr. Markita Broyles –	participating in person
Dr. Theresa Garton –	participating in person
Dr. Megan Hanner –	participating in person
Dr. Lynn Mitchell –	participating in person
Dr. John Muchmore –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. James Osborne –	participating in person

## Viewing Access Only via Zoom:

Please register for the meeting at:

[https://zoom.us/webinar/register/WN\\_dgGOMPbDRuuDIZWND8TjHQ](https://zoom.us/webinar/register/WN_dgGOMPbDRuuDIZWND8TjHQ)

Or join by phone:

Dial: +1-602-753-0140 or +1-669-219-2599

Webinar ID: 976 8930 3413

Passcode: 02133264

## Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at [www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board](http://www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board) and completing the [Speaker Registration Form](#). Completed Speaker Registration forms should be submitted to [DURPublicComment@okhca.org](mailto:DURPublicComment@okhca.org). Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.

Items to be presented by Dr. Muchmore, Chairman:

### **2. Public Comment Forum**

- A. Acknowledgment of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

### **3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A**

- A. May 12, 2021 DUR Minutes – Vote
- B. May 12, 2021 DUR Recommendation Memorandum
- C. Correspondence

Items to be presented by Dr. Smith, Dr. Muchmore, Chairman:

### **4. Medication Therapy Management (MTM) Program Update – See Appendix B**

- A. MTM Program Update
- B. Focus on Adherence
- C. Case Study
- D. Summary

Items to be presented by Dr. Nawaz, Dr. Daniel, Dr. Muchmore, Chairman:

### **5. Update on Medication Coverage Authorization Unit/Use of Glucagon-Like Peptide-1 (GLP-1) Agonists/Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors with Cardiovascular (CV) Benefit in Members with Type 2 Diabetes (T2D) and High CV Risk or Established Atherosclerotic CV Disease (ASCVD) Mailing Update – See Appendix C**

- A. Pharmacy Helpdesk Activity for May 2021
- B. Medication Coverage Activity for May 2021
- C. Use of GLP-1 Agonists/SGLT-2 Inhibitors with CV Benefit in Members with T2D and High CV Risk or Established ASCVD Mailing Update

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

**6. Action Item – Vote to Prior Authorize Cabometyx® (Cabozantinib), Fotivda® (Tivozanib), Jelmyto® (Mitomycin), and Padcev® (Enfortumab Vedotin-ejfv) – See Appendix D**

- A. Market News and Updates
- B. Product Summaries
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

**7. Action Item – Vote to Prior Authorize Gemtesa® (Vibegron) – See Appendix E**

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

**8. Action Item – Vote to Prior Authorize Zilxi® (Minocycline 1.5% Topical Foam) – See Appendix F**

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

**9. Action Item – Vote to Prior Authorize Kynmobi™ (Apomorphine) and Ongentys® (Opicapone) – See Appendix G**

- A. New U.S. Food and Drug Administration (FDA) Approval(s)
- B. Product Summaries
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

**10. Action Item – Vote to Prior Authorize Fetroja® (Cefiderocol) and Kimyrsa™ (Oritavancin) – See Appendix H**

- A. New U.S. Food and Drug Administration (FDA) Approval(s)
- B. Product Summaries
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Daniel, Dr. Muchmore, Chairman:

**11. Annual Review of the SoonerCare Pharmacy Benefit – See Appendix I**

- A. Summary
- B. Medicaid Drug Rebate Program
- C. Alternative Payment Models
- D. Drug Approval Trends
- E. Traditional Versus Specialty Pharmacy Products
- F. Top 10 Traditional Therapeutic Classes by Reimbursement
- G. Top 10 Specialty Therapeutic Classes by Reimbursement
- H. Top 10 Medications by Reimbursement
- I. Cost Per Claim
- J. Market Projections

- K. Conclusion
- L. Top 50 Reimbursed Drugs by Calendar Year
- M. Top 50 Medications by Total Number of Claims
- N. Top 10 Traditional and Specialty Therapeutic Categories by Calendar Year
- O. Calendar Year Age Group Comparison

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

**12. Annual Review of Attention-Deficit/Hyperactivity Disorder (ADHD) and Narcolepsy Medications and 30-Day Notice to Prior Authorize Azstarys™ (Serdexmethylphenidate/Dexmethylphenidate), Qelbree™ (Viloxazine), and Xywav™ (Calcium/Magnesium/Potassium/Sodium Oxybates) –**

**See Appendix J**

- A. Current Prior Authorization Criteria
- B. Utilization of ADHD and Narcolepsy Medications
- C. Prior Authorization of ADHD and Narcolepsy Medications
- D. Oklahoma Resources
- E. Market News and Updates
- F. Product Summaries
- G. College of Pharmacy Recommendations
- H. Utilization Details of ADHD and Narcolepsy Medications

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

**13. Annual Review of Atypical Antipsychotic Medications and 30-Day Notice to Prior Authorize Lybalvi™ (Olanzapine/Samidorphan) – See Appendix K**

- A. Current Prior Authorization Criteria
- B. Utilization of Atypical Antipsychotic Medications
- C. Prior Authorization of Atypical Antipsychotic Medications
- D. Oklahoma Resources
- E. Market News and Updates
- F. Lybalvi™ (Olanzapine/Samidorphan) Product Summary
- G. College of Pharmacy Recommendations
- H. Utilization Details of Atypical Antipsychotic Medications

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

**14. Annual Review of Various Special Formulations and 30-Day Notice to Prior Authorize Alkindi® Sprinkle (Hydrocortisone Oral Granule), Eysuvis® (Loteprednol 0.25% Ophthalmic Suspension), Gimoti™ (Metoclopramide Nasal Spray), Nextstellis® (Drospirenone/Estetrol Tablet), Ozobax® (Baclofen 5mg/mL Oral Solution), Phexxi® (Lactic Acid/Citric Acid/Potassium Bitartrate Vaginal Gel), RediTrex® (Methotrexate Injection), Reltone™ (Ursodiol Capsule), and Thyquidity™ (Levothyroxine Oral Solution) – See Appendix L**

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Various Special Formulations
- D. Prior Authorization of Various Special Formulations
- E. Product Summaries
- F. College of Pharmacy Recommendations
- G. Utilization Details of Various Special Formulations

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

**15. Annual Review of Anti-Ulcer Medications and 30-Day Notice to Prior Authorize Helidac® Therapy (Bismuth Subsalicylate/Metronidazole/Tetracycline Dose Pack) and Pylera™ (Bismuth Subcitrate Potassium/Metronidazole/Tetracycline Capsule) – See Appendix M**

- A. Current Prior Authorization Criteria
- B. Utilization of Anti-Ulcer Medications
- C. Prior Authorization of Anti-Ulcer Medications
- D. Market News and Updates
- E. *Helicobacter Pylori* (*H. Pylori*) Product Summaries
- F. Cost Comparison: *H. Pylori* Regimens
- G. College of Pharmacy Recommendations
- H. Utilization Details of Anti-Ulcer Medications

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

**16. Annual Review of Isturisa® (Osilodrostat) – See Appendix N**

- A. Current Prior Authorization Criteria
- B. Utilization of Isturisa® (Osilodrostat)
- C. Prior Authorization of Isturisa® (Osilodrostat)
- D. Market News and Updates
- E. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

**17. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix O**

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

**18. Future Business\* (Upcoming Product and Class Reviews)**

- A. Intravenous (IV) Iron Products
- B. Ophthalmic Anti-Inflammatories
- C. Opioid Analgesics and Medication-Assisted Treatment (MAT) Medications
- D. Topical Corticosteroids

*\*Future product and class reviews subject to change.*

**19. Adjournment**

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.